Open AccessThe efficiency of non-specific inhaled immunotherapy with ruzam in patients with atopic bronchialasthma
Author(s) -
Д. В. Терехов,
Н. М. Ненашева,
Natalia Nenasheva
Publication year - 2011
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja848
Subject(s) - medicine , spirometry , sputum , asthma , bronchial hyperresponsiveness , placebo , nebulizer , inhalation , inflammation , morning , gastroenterology , immunology , anesthesia , respiratory disease , lung , pathology , tuberculosis , alternative medicine
Background. To study the efficacy and safety of inhaled form of ruzam in adult patients with persistent mildand moderate atopic bronchial asthma (ba).Materials and methods. a placebo-controlled prospective, randomized, open label study of an efficacy of ruzama solution for inhalations (in bottles on 2,5 or 5 ml) on 2,5 ml onсe a day through nebulizer during 2 weeks wasconducted in adult asthmatic patients. The efficacy of therapy was evaluated by dynamics of symptoms and requirementin 2-agonists, besides PEfr, spirometry, bronchial hyperresponsiveness (bhr), asthma control test(aCT ), level of the markers of the allergic inflammation were performed.Results. reduction of bа symptoms, increase morning PEfr, decrease of bhr and NОex level in patients whoreceived ruzam compared with control group was observed. achievement of clinical control of bа in patientstreated by ruzam was accompanied by statistically significant positive dynamics of markers of inflammation(ifNg, ECP) in blood serum and in supernatant of the induced sputum. it testifies about anti-inflammatory influenceof ruzam.Conclusion. inhaled therapy with ruzam in a complex with iNCs basic therapy is an effective and safe methodof treatment of persistent atopic bronchial asthma. This combination allows to reach clinical and functionalcontrol of ba faster and to reduce inflammation markers in blood serum and induced sputum.